HIV viral non-suppression and drug resistance among persons who inject drugs on dolutegravir antiretroviral therapy in Kenya
Among PWID living with HIV on TLD in Kenya, one-third had intermittent or sustained viral non-suppression across two years of follow-up. While NNRTI resistance was common, DTG resistance mutations were rare. Improving viral suppression among PWID living with HIV will reduce transmission risks and improve clinical outcomes.
Authors
- David Edgar Kimani
- Ceejay L. Boyce (ORCID: https://orcid.org/0000-0002-3716-8216)
- Frenkel Lisa
- Esther Gitau
- Bhavna Chohan (ORCID: https://orcid.org/0000-0002-2125-6799)
- Geoffrey S. Gottlieb (ORCID: https://orcid.org/0000-0002-5749-481X)
- Betsy Sambai (ORCID: https://orcid.org/0000-0003-2100-4943)
- Loice Mbogo (ORCID: https://orcid.org/0000-0001-5916-7188)
- Paul Drain
- Stephen E. Hawes
- Brandon L. Guthrie
- Robert A. Smith
- William Sinkele D. Min
- Vincent Adhanja
- Sarah Masyuko
- Vincent C. Marconi
- Aliza Monroe-Wise
- Carey Farquhar
Institutions
- Emory University (US)
- University of Washington (US)
- Partners for Health and Development in Africa (KE)
- Ministry of Health (KE)
- United States International University Africa (KE)
- Seattle University (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-03-02
- DOI
- https://doi.org/10.64898/2026.02.26.26347230
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Emory University
- National Institutes of Health
- Center for AIDS Research, University of Washington